先看重點
彙總12項隨機對照試驗、共974名成年糖尿病患者,與單純常規治療相比,應用介入使糖化血紅蛋白(HbA1c)降低0.48%(95%置信區間0.19%至0.77%),且未增加不良事件。不同功能的比較屬探索性亞組分析,涉及試驗很少,只能提示假設,不能證明哪種設計更好。
證據類型
隨機試驗統合分析
解讀依據
公開摘要
閱讀重點
方法與適用範圍
研究在問什麼
糖尿病應用的功能差別很大,此前既沒有統一的分類方法,也不清楚哪些功能對血糖有幫助。研究者先建立了應用功能分類,再檢驗應用能把糖化血紅蛋白降低多少,以及哪些功能與更大的降幅相關。
研究對象與方法
這是一項系統綜述,採用隨機效應模型做統合分析。研究者先建立了三軸分類(臨床模組、功能模組、帶風險評估的具體功能),並透過歸類市售糖尿病應用進行驗證。隨後檢索MEDLINE、EMBASE、Cochrane對照試驗中心註冊庫、中國生物醫學文獻資料庫和ClinicalTrials.gov中2007年1月至2016年5月的文獻,納入比較應用介入與單純常規治療、受試者為成年糖尿病門診患者的隨機對照試驗。彙總糖化血紅蛋白的均數差和不良事件的風險比,並按各模組有無做探索性亞組分析。
主要發現
以下為作者報告的結果。數值須連同族群和不確定性一起閱讀。
- 112項試驗共974名參與者,應用介入與糖化血紅蛋白降低0.48%相關(95%置信區間0.19%至0.77%),未增加不良事件。
- 22型糖尿病患者的降幅(0.67%,95%置信區間0.30%至1.03%)大於1型糖尿病患者(0.36%,95%置信區間0.08%至0.81%)。
- 3帶併發症預防模組的應用降幅更大(1.31%,95%置信區間0.66%至1.96%),不帶該模組者為0.38%(95%置信區間0.09%至0.67%;亞組間P=.01)。結構化資料展示也與更大降幅相關(0.69%對0.16%;P=.03)。
- 4臨床決策功能與更大降幅無關(有該功能為0.18%,無為0.61%;P=.10)。
限制與不確定性
- 1僅12項試驗,每個亞組比較只依賴少數研究,不少置信區間很寬。
- 2模組比較是探索性的,也不是隨機分配;帶某模組的應用往往在其他方面也不同,因此不一定是該模組起作用。
- 3摘要中個別區間與點估計看起來不一致(例如0.16%的區間下限也是0.16%),亞組數字需謹慎解讀。
- 4本解讀僅基於摘要;試驗質量、追蹤時長和異質性未報告。
日常健康啟示
平均而言,在常規治療之外使用應用,糖化血紅蛋白有小幅下降,在2型糖尿病中訊號更強。這一結果無法告訴你該選哪款應用,也不意味著應用可以代替診療;調整任何管理方式前,應與你的糖尿病診療團隊商量。
如何連結自己的資料
如果你在應用中記錄血糖、飲食或用藥,真正有用的比較是自己數月內的糖化血紅蛋白或血糖趨勢,並使用同一血糖儀或連續血糖監測裝置、相近的測量條件。單次讀數波動太大,不足以評價一款應用。
如何理解這類證據
合併試驗可提高精確度,但族群、對照、偏誤與不確定性仍重要;網路排名包含間接證據,不是通用最佳方案。
作者的結構化摘要 English
以下英文摘要依所記錄的開放授權轉載,屬於作者原始材料,並非 MoveVitals 解讀。上方已提供研究解讀,分別說明作者結果與本站解釋;重要結論可直接查核原文。
Background
Mobile health apps for diabetes self-management have different functions. However, the efficacy and safety of each function are not well studied, and no classification is available for these functions.
Objective
The aims of this study were to (1) develop and validate a taxonomy of apps for diabetes self-management, (2) investigate the glycemic efficacy of mobile app-based interventions among adults with diabetes in a systematic review of randomized controlled trials (RCTs), and (3) explore the contribution of different function to the effectiveness of entire app-based interventions using the taxonomy.
Methods
We developed a 3-axis taxonomy with columns of clinical modules, rows of functional modules and cells of functions with risk assessments. This taxonomy was validated by reviewing and classifying commercially available diabetes apps. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Chinese Biomedical Literature Database, and ClinicalTrials.gov from January 2007 to May 2016. We included RCTs of adult outpatients with diabetes that compared using mobile app-based interventions with usual care alone. The mean differences (MDs) in hemoglobin A_(1c) (HbA_(1c)) concentrations and risk ratios of adverse events were pooled using a random-effects meta-analysis. After taxonomic classification, we performed exploratory subgroup analyses of the presence or absence of each module across the included app-based interventions.
Results
Across 12 included trials involving 974 participants, using app-based interventions was associated with a clinically significant reduction of HbA_(1c) (MD 0.48%, 95% CI 0.19%-0.77%) without excess adverse events. Larger HbA_(1c) reductions were noted among patients with type 2 diabetes than those with type 1 diabetes (MD 0.67%, 95% CI 0.30%-1.03% vs MD 0.36%, 95% CI 0.08%-0.81%). Having a complication prevention module in app-based interventions was associated with a greater HbA_(1c) reduction (with complication prevention: MD 1.31%, 95% CI 0.66%-1.96% vs without: MD 0.38%, 95% CI 0.09%-0.67%; intersubgroup P=.01), as was having a structured display (with structured display: MD 0.69%, 95% CI 0.32%-1.06% vs without: MD 0.16%, 95% CI 0.16%-0.48%; intersubgroup P=.03). However, having a clinical decision-making function was not associated with a larger HbA_(1c) reduction (with clinical decision making: MD 0.18%, 95% CI 0.21%-0.56% vs without: MD 0.61%, 95% CI 0.27%-0.95%; intersubgroup P=.10).
Conclusions
The use of mobile app-based interventions yields a clinically significant HbA_(1c) reduction among adult outpatients with diabetes, especially among those with type 2 diabetes. Our study suggests that the clinical decision-making function needs further improvement and evaluation before being added to apps.
來源與署名
Mobile App-Based Interventions to Support Diabetes Self-Management: A Systematic Review of Randomized Controlled Trials to Identify Functions Associated with Glycemic Efficacy.
Wu Y, Yao X, Vespasiani G, Nicolucci A, Dong Y, Kwong J, Li L, Sun X, Tian H, Li S.
JMIR mHealth and uHealth · 2017-03-14
DOI: 10.2196/mhealth.6522 ↗PubMed · 28292740 ↗Europe PMC · 所記錄的開放授權: cc by ↗摘要著作權歸原作者,依來源紀錄的開放授權轉載。中文譯文協助閱讀,英文摘要供查核術語及具體數值;本站的方法學解釋與作者結論分別呈現。
MoveVitals 編輯解讀 · 健康教育內容 · 未記錄個人臨床審閱
來源查核日期 2026-11-01
實用健康指南
放在一起讀
更早的進食視窗與更大的體重和胰島素獲益相關,優於晚間進食
彙總41項隨機對照試驗(2287名參與者,介入時間中位數8週)發現,限時進食比日常飲食體重低2.15 kg(95%置信區間−2.56至−1.74),而早吃比晚吃體重多降1.15 kg(95%置信區間−1.86至−0.45)。多數試驗較短,只有6個研究組檢驗了早間進食,結局是身體和血液指標,不是心臟病發作或死亡。
BMJ Medicine
限熱量飲食再加上午8點至下午4點進食視窗,1年減重無明顯額外優勢
139名肥胖患者都按限制熱量的飲食進食,其中一組再加上上午8:00至下午4:00的進食視窗,12個月平均體重變化為−8.0 kg,單純限熱量組為−6.3 kg。淨差值−1.8 kg(95%置信區間−4.0至0.4;P=0.11)無統計學意義,該區間既不能排除視窗確有獲益,也不能排除毫無作用。
The New England Journal of Medicine
20人住院試驗:超加工飲食讓人每天多攝取508 kcal並增重
20名成年人在醫院研究病房住了28天,兩種選單各吃2週、想吃多少吃多少:超加工選單讓他們每天多攝取508 kcal(±106,標準誤,P=0.0001),體重增加0.9 kg;未加工選單則讓體重減輕0.9 kg。樣本小、週期短、食物全程由研究方提供,既不能說明日常生活中的長期結果,也無法確定是食物的哪種特點導致多吃。
Cell Metabolism
地中海飲食加橄欖油或堅果與心血管事件減少相關(更正後的試驗)
在7447名55至80歲、心血管風險較高的西班牙成年人中,被分到加特級初榨橄欖油(風險比0.69,95%置信區間0.53至0.91)或加堅果(風險比0.72,0.54至0.95)的地中海飲食組,發生主要心血管事件的風險低於被告知減少脂肪的對照組。試驗存在隨機化失誤,2013年的報告已撤回並重新估算,證據有力但並不完美。
The New England Journal of Medicine

